In this study, compared with patients with moderate COVID-19, those severe to critical patients showed elder age, active cellular immunity (lower lymphocyte but higher CD3+CD19−level), and increased inflammatory response [higher neutrophil and interleukin-6 (IL-6) level)] at the baseline (Table 2). This evidence concerns the gene IL6 and COVID-19.